Abbott/La Jolla LJP 394
Executive Summary
Phase II/III clinical trial of LJP 394 for the treatment of lupus nephritis is halted. According to the data safety committee overseeing the trial, while preliminary results showed LJP 394 lowered circulating antibodies to double-stranded DNA in patients, the committee found it unlikely that LJP 394 would show a statistically significant reduction in renal flares, the primary endpoint. There are more than 200 patients currently enrolled. Both companies are conducting a review of the data which could take several months to complete, and are continuing a Phase II dose-ranging study for LJP 394 with 75 lupus patients. That study is expected to be completed by fall
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth